Drug use evaluation of etamsylate based on weighted TOPSIS method

Published on Dec. 30, 2023Total Views: 519 times Total Downloads: 323 times Download Mobile

Author: Hai-Jin HU ¹ Mei-Juan LI ² Tong XING ³  Jin-Hua ZHANG ⁴

Affiliation: 1. Department of Pharmacy, Beijing Beiya Orthopaedic Hospital, Beijing 102445, China 2. Department of Pharmacy, The First Hospital of Shanxi Medical University, Taiyuan 030001, China 3. Department of Vascular Surgery, Beijing Beiya Orthopaedic Hospital, Beijing 102445, China 4. Department of Pharmacy, Fujian Maternity and Child Health Hospital, Fuzhou 350001, China

Keywords: Etamsylate for injection Weighted TOPSIS method Attribute hierarchy model Drug use evaluation

DOI: 10.19960/j.issn.1005-0698.202312004

Reference: Hai-Jin HU, Mei-Juan LI, Tong XING, Jin-Hua ZHANG.Drug use evaluation of etamsylate based on weighted TOPSIS method[J].Yaowu Liuxingbingxue Zazhi,2023, 32(12):1347-1353 .DOI: 10.19960/j.issn.1005-0698.202312004.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Objective To establish drug use evaluation (DUE) standard of etamsylate and to evaluate the use of etamsylate by weighted superior and inferior solution distance (TOPSIS) method, so as to provide a basis for promoting its clinical rational use.

Methods Based on the instructions of etamsylate for injection, the DUE criteria of etamsylate were established according to the relevant guidelines of hemostasis at home and abroad, evidence-based literature and expert consultation. The weighted TOPSIS method based on the attribute hierarchy model was used to evaluate the utilization of etamsylate in Beijing Beiya Orthopaedic Hospital.

Results Among the 119 cases, 2 cases (1.68%) were with the relative closeness degree between each case and the optimal regimen (C_i) no less than 0.8, which was evaluated as reasonable; 70 cases (58.82%) were with the C_i ranging between 0.8 and 0.6, which was evaluated as basically reasonable; 47 cases (39.50%) were with the C_i less than 60%, which was evaluated as unreasonable. The top three unreasonable rates were dose and frequency (66.39%), configuration method (49.58%), and drug interaction (24.37%).

Conclusion The method of DUE of etamsylate based on weighted TOPSIS method can synthesize several evaluation indexes, and the evaluation method is simple and flexible. The rational rate of use of etamsylate in this hospital is low, especially there are problems in configuration method, administration dose and frequency, drug interaction, treatment course and so on, and the management still needs to be strengthened.

Full-text

Please download the PDF version to read the full text: download

References

1.非创伤性出血急诊处理专家组. 非创伤性出血的急诊处理专家共识/意见[J]. 中华急诊医学杂志, 2017, 26(8): 850-856. DOI: 10.3760/cma.j.issn.1671-0282. 2017.08.002.

2.中国医疗保健国际交流促进会泌尿健康促进分会. 泌尿外科腹腔镜手术围手术期出血防治专家共识[J]. 现代泌尿外科杂志, 2021, 26(6): 463-468. DOI: 10.3969/j.issn.1009-8291.2021.06.003.

3.中华医学会神经外科学分会. 神经外科围手术期出血防治专家共识(2018)[J]. 中华医学杂志, 2018, 98(7): 483-495. DOI: 10.3760/cma.j.issn.0376-2491. 2018.07.002.

4.李继超, 尹东, 黄宇, 等. 酚磺乙胺联合氨甲苯酸对初次单侧全膝关节置换术后出血量影响的临床研究[J]. 中国矫形外科杂志, 2014, 22(17): 1580-1583. [Li JC, Yin D, Huang Y, et al. Blood loss control using etamsylate and aminomethylbenzoic acid during primary unilateral total knee arthroplasty[J]. Orthopedic Journal of China, 2014, 22(17): 1580-1583.] DOI: 10.3977/j.issn.1005-8478.2014.17.09.

5.陈新谦, 金有豫, 汤光, 主编. 新编药物学, 第16版[M]. 北京: 人民卫生出版社, 2006: 569.

6.罗玉萍, 李作东. 酚磺乙胺注射液与常用制酸药物的配伍稳定性[J]. 今日药学, 2011, 21(3): 165-166. [Luo YP, Li ZD. Study on compatibility of combined use of etamsylate injection with anti-acid drug[J]. Pharmacy Today, 2011, 21(3): 165-166.] DOI: CNKI:SUN:YAXU.0. 2011-03-019.

7.梁晓丽, 封宇飞. 酚磺乙胺致过敏性休克13例文献分析[J]. 中国现代医药杂志, 2008, 10(12): 15-17. [Liang XL, Feng YF. Literature analysis of ethamsylate-induced anaphylactic shock in 13cases[J]. Modern Medicine Journal of China, 2008, 10(12): 15-17.] DOI: 10.3969/j.issn.1672-9463.2008.12.005.

8.中国医师协会心血管外科医师分会, 中国医师协会心血管外科分会大血管外科专业委员会. 心脏外科手术血液管理专家共识[J]. 中华胸心血管外科杂志, 2015, 31(12): 715-718. DOI: 10.3760/cma.j.issn.1001-4497. 2015.12.002.

9.Garay RP, Chiavaroli C, Hannaert P. Therapeutic efficacy and mechanism of action of ethamsylate, a long-standing hemostatic agent[J]. Am J Ther, 2006, 13(3): 236-247. DOI: 10.1097/01.mjt.0000158336.62740.54.

10.刘圣, 付先明, 主编. 静脉用药调配技术[M]. 合肥: 安徽科技出版社, 2015: 424-425.

11.焦万田, 主编. 新编简明药物手册[M]. 北京: 金盾出版社, 2009: 523-524.

12.王桂凤, 李雪芹, 刘锐锋, 等. 基于加权TOPSIS法的硫酸多黏菌素B药物利用评价[J]. 中国医院药学杂志, 2022, 42(3): 324-328. [Wang GF, Li XQ, Liu RF, et al. Drug use evaluation of polymyxin B sulphas for injection based on weighted TOPSIS method[J]. Chinese Journal of Hospital Pharmacy, 2022, 42(3): 324-328.] DOI: 10.13286/j.1001-5213.2022.03.18.

13.李建明, 刘庆欧, 曲成毅. 综合评价中两种指标权重的确定方法--相似权法和属性AHM赋权法[J]. 山西医药杂志, 2004, 33(6): 492-494. [Li JM, Liu QO, Qu CY. Two methods of determining index weight in comprehensive evaluation: similar weight method and attribute AHM weighting method[J]. Shanxi Medical Journal, 2004, 33(6): 492-494.] DOI: 10.3969/j.issn.0253-9926.2004.06.015.

14.王桂凤, 李雪芹, 刘锐锋, 等. 基于加权TOPSIS法的利奈唑胺葡萄糖注射液药物利用评价[J]. 中国医院药学杂志, 2021, 41(23): 2464-2468. [Wang GF, Li XQ, Liu RF, et al. Evaluation of drug use of linezolid injection baseduon weighted TOPSIS method[J]. Chinese Journal of Hospital Pharmacy, 2021, 41(23): 2464-2468.] DOI: 10.13286/j.1001-5213.2021.23.14.

15.赵小丽, 朱倩倩, 赵佩, 等. 基于加权TOPSIS法评价重组人血小板生成素的合理使用[J]. 中国医院药学杂志, 2022, 42(4): 431-434. [Zhao XL, Zhu QQ, Zhao P, et al. Evaluation of recombinant human thrombopoietin utilization based on weighted TOPSIS method[J]. Chinese Journal of Hospital Pharmacy, 2022, 42(4): 431-434.] DOI: 10.13286/j.1001-5213.2022.04.16.

16.中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组,中华医学会神经病学分会神经血管介入协作组 .中国蛛网膜下腔出血诊治指南2019[J]. 中华神经科杂志, 2019, 52(12): 1006-1021. DOI: 10.3760/cma.j.issn.1006-7876.2019.12.004.

17.蔡雪峰, 伍三兰. 围手术期止血药的合理应用[J]. 中国医院药学杂志, 2010, 30(14): 1225-1228. [Cai XF, Wu SL. Rational application of perioperative hemostatic[J]. Chinese Journal of Hospital Pharmacy, 2010, 30(14): 1225-1228.] DOI: CNKI:SUN:ZGYZ.0.2010-14-022.

18.阮清锋, 邓元央. 外伤性脑梗死诊治现状及进展[J]. 右江医学, 2008, 36(2): 209-211. [Ruan QF, Deng YY. Current status and progress of diagnosis and treatment of traumatic cerebral infarction[J]. Youjiang Medical Journal, 2008, 36(2): 209-211.] DOI: 10.3969/j.issn.1003-1383. 2008.02.056.